Eamonn Hobbs

Founder at ImmunSYS, Inc.

65 year

Health Technology

Commercial Services

Miscellaneous

Active connections

Name	Gender	Age	Linked companies	Collaboration
Douglas G. Watson	M	79	DELCATH SYSTEMS, INC. ORASURE TECHNOLOGIES, INC. ImmunSYS, Inc. ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. Syncromune, Inc. Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.	15 years
Charles Link	M	64	Syncromune, Inc. Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020. ImmunSYS, Inc. ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.	4 years
Agustin Gago	M	64	DELCATH SYSTEMS, INC. ANGIODYNAMICS, INC. ImmunSYS, Inc. ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. E-Z-EM, Inc. E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. Syncromune, Inc. Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.	21 years
Marlene Wright Barton	F	-	ImmunSYS, Inc. ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. Syncromune, Inc. Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.	6 years
Howard Donnelly	M	63	ANGIODYNAMICS, INC.	20 years
Carrie Manner	F	50	ORASURE TECHNOLOGIES, INC.	2 years
Mara Aspinall	F	61	ORASURE TECHNOLOGIES, INC.	7 years
Nancy Gagliano	M	64	ORASURE TECHNOLOGIES, INC.	3 years
Stephen Trowbridge	M	49	ANGIODYNAMICS, INC.	16 years
Christopher Davey	M	-	Marvao Medical Devices Ltd. Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.	18 years
Roger Hatfield	M	78	Marvao Medical Devices Ltd. Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.	-
Igor Keselman	M	-	ImmunSYS, Inc. ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.	-
Lelio Marmora	M	57	ORASURE TECHNOLOGIES, INC.	4 years
John Burns	M	-	Marvao Medical Devices Ltd. Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.	-
Wesley Johnson	M	65	ANGIODYNAMICS, INC.	17 years
Stefano Taucer	M	-	ORASURE TECHNOLOGIES, INC.	2 years
Ann Marie Cannon	F	-	Marvao Medical Devices Ltd. Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.	-
Jim Datin	M	61	ORASURE TECHNOLOGIES, INC.	5 years
David Shulkin	M	64	ORASURE TECHNOLOGIES, INC.	4 years
Jeffrey L. Cleland	M	59	ImmunSYS, Inc. ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. Syncromune, Inc. Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.	-
Joseph C. Maroon	M	83	ImmunSYS, Inc. ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. Syncromune, Inc. Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.	-
Mark A. Saab	M	-	Marvao Medical Devices Ltd. Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.	18 years
Norman Schwartz	M	74	ImmunSYS, Inc. ImmunSYS, Inc. Pharmaceuticals: MajorHealth Technology ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL. Syncromune, Inc. Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.	-
Zachary Wert	M	-	ORASURE TECHNOLOGIES, INC.	2 years
John Kirwan	M	-	Hobbs Medical Ventures, LLC Hobbs Medical Ventures, LLC Miscellaneous Commercial ServicesCommercial Services Hobbs Medical Ventures, LLC provides consulting services for the pharmaceutical industry. The private company is based in New York, NY. The company was founded by Eamonn P. Hobbs.	2 years
Kenneth McGrath	M	52	ORASURE TECHNOLOGIES, INC.	2 years
Leonard Mermel	M	-	Marvao Medical Devices Ltd. Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.	-
Jeffrey Hoggard	M	-	Marvao Medical Devices Ltd. Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.	-
James O'Reilly	M	-	Harmonic Medical, Inc. Harmonic Medical, Inc. Medical SpecialtiesHealth Technology Harmonic Medical, Inc. develops non-invasive surgery treatment for uterine fibroids. It also treats broad range of cancer treatment such as bone metastases, metastic liver cancer, hepatocellular carcinoma, thyroid cancer, pancreatic cancer, and kidney cancer. The company is headquartered in Toronto, Canada.	11 years
Johnny John	M	60	DELCATH SYSTEMS, INC.	12 years
Micheal Kelly	M	-	Marvao Medical Devices Ltd. Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.	-
Paul T. Kostecki	M	74	University of Massachusetts	44 years
Trace Custer	F	-	ORASURE TECHNOLOGIES, INC.	2 years
David A. Rappaport	M	-	ORASURE TECHNOLOGIES, INC.	6 years
Gregory Champion	M	69	Syncromune, Inc. Syncromune, Inc. Pharmaceuticals: MajorHealth Technology Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.	-
Mick McEnroe	M	-	Marvao Medical Devices Ltd. Marvao Medical Devices Ltd. Medical SpecialtiesHealth Technology Marvao Medical Devices Ltd. designs develop and markets novel medical devices. It provides products include NexSite 9Fr dual and NexSitetm 8Fr single lumen central venous catheters, as well as NexSite hemodialysis and drainage catheters. The company was founded by Christopher Davey and Mark A. Saab in 2006 and is headquartered in Dublin, Ireland.	-

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Peter J. Graham	M	57	ANGIODYNAMICS, INC. E-Z-EM, Inc. E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY. ANTARES PHARMA, INC. DELCATH SYSTEMS, INC.	24 years
Stephen Tang	M	63	ORASURE TECHNOLOGIES, INC.	11 years
D. Joseph Gersuk	M	74	ANGIODYNAMICS, INC.	6 years
Ronald Spair	M	58	ORASURE TECHNOLOGIES, INC.	17 years
William M. Appling	M	61	North American Instrument Corp. DELCATH SYSTEMS, INC.	6 years
Jennifer Simpson	M	55	DELCATH SYSTEMS, INC.	8 years
Scott Gleason	M	45	ORASURE TECHNOLOGIES, INC.	2 years
Keith David Hartt	M	63	University of Massachusetts	14 years
Jack E. Jerrett	M	65	ORASURE TECHNOLOGIES, INC.	21 years
Agnieszka Gallagher	F	51	ORASURE TECHNOLOGIES, INC.	1 years
Richard Taney	M	68	DELCATH SYSTEMS, INC.	4 years
Johannes Keltjens	M	67	ANGIODYNAMICS, INC.	2 years
David McDonald	M	63	DELCATH SYSTEMS, INC. ANGIODYNAMICS, INC.	5 years
Barbra Keck	F	46	DELCATH SYSTEMS, INC.	11 years
John Purpura	M	62	DELCATH SYSTEMS, INC.	15 years
Graham Miao	M	60	DELCATH SYSTEMS, INC.	3 years
Kaushik J. Dave	M	63	ANTARES PHARMA, INC.	5 years
Michael Celano	M	65	ORASURE TECHNOLOGIES, INC.	16 years
Kin Yip Leung	M	63	DELCATH SYSTEMS, INC.	3 years
Paul Wotton	M	63	ANTARES PHARMA, INC.	10 years
Douglas Michels	M	66	ORASURE TECHNOLOGIES, INC.	14 years
Roger Stoll	M	81	DELCATH SYSTEMS, INC.	16 years
Jennifer Stacey	F	59	ANTARES PHARMA, INC.	1 years
Robert P. Roche	M	68	ANTARES PHARMA, INC.	9 years
Marvin Samson	M	82	ANTARES PHARMA, INC.	7 years
Ronny Lancaster	M	72	ORASURE TECHNOLOGIES, INC.	19 years
Donald G. Coffey	M	69	University of Massachusetts	6 years
Michael S. Sharp	M	-	ANGIODYNAMICS, INC.	3 years
John J. Howarth	M	-	ANTARES PHARMA, INC.	8 years
Krishna Kandarpa	M	73	Society of Interventional Radiology Society of Interventional Radiology Miscellaneous Commercial ServicesCommercial Services The Society of Interventional Radiology is a national organization based in Fairfax, VA, consisting of physicians, scientists, and allied health professionals. The company is dedicated to improving public health through disease management and minimally invasive, image-guided therapeutic interventions. DELCATH SYSTEMS, INC.	10 years
Daniel Moore	M	63	The Medical Device Manufacturers Association The Medical Device Manufacturers Association Miscellaneous Commercial ServicesCommercial Services The Medical Device Manufacturers Association operates as a trade association. The private company is based in Washington. The American company was founded by Thomas C. Thompson.	7 years
Anthony Zezzo	M	70	ORASURE TECHNOLOGIES, INC.	9 years
Anne Michelle Whitaker	F	56	ORASURE TECHNOLOGIES, INC.	2 years
Akbar Moawalla	M	-	University of Massachusetts	6 years
Jonathan S. Jaffe	M	-	ANTARES PHARMA, INC.	9 years
Cuneyt Oge	M	-	University of Massachusetts	6 years
Aradhana Sarin	M	50	ORASURE TECHNOLOGIES, INC.	-
Steven H. Gardner	M	-	University of Massachusetts	6 years
Joseph G. Gerardi	M	62	ANGIODYNAMICS, INC.	-
Jeffrey G. Gold	M	76	ANGIODYNAMICS, INC.	22 years
Roger L. Pringle	M	83	ORASURE TECHNOLOGIES, INC.	17 years
Dennis Meteny	M	70	ANGIODYNAMICS, INC.	20 years
Charles W. Patrick	M	69	ORASURE TECHNOLOGIES, INC.	14 years
Arthur Rosenthal	M	77	Cappella, Inc. Cappella, Inc. Pharmaceuticals: MajorHealth Technology Cappella, Inc. operates as a medical device company, which develops novel solutions for the treatment of complex coronary artery disease (CAD) and specifically bifurcation vascular disease. The company was founded by Antonio Columbo and Ascher Shmulewitz in 2004 and is headquartered in Boston, MA.	2 years
Steven R. LaPorte	M	73	ANGIODYNAMICS, INC.	-
Anastasios Konidaris	M	57	DELCATH SYSTEMS, INC.	2 years
Vincent A. Bucci	M	69	ANGIODYNAMICS, INC.	7 years
Howard S. Stern	M	93	ANGIODYNAMICS, INC.	17 years
Robert Ladd	M	65	DELCATH SYSTEMS, INC.	6 years
David P. Meyers	M	60	ANGIODYNAMICS, INC. E-Z-EM, Inc. E-Z-EM, Inc. Medical SpecialtiesHealth Technology E-Z-EM, Inc. develops, manufactures and markets diagnostic imaging products. The firm's products are used for computed tomography and magnetic resonance imaging, colorectal cancer screening, evaluation of swallowing disorders and testing for other diseases, and disorders of the gastrointestinal system. The company was founded in 1961 and is headquartered in Lake Success, NY.	12 years
Laura Brege	F	66	DELCATH SYSTEMS, INC.	2 years
Roberto Cuca	M	57	ORASURE TECHNOLOGIES, INC.	3 years
Harold C. Mapes	M	64	DELCATH SYSTEMS, INC. ANGIODYNAMICS, INC.	21 years
Rick Scafidi	M	-	University of Massachusetts	4 years
Dario N. R. Carrara	M	60	ANTARES PHARMA, INC.	15 years
Michael Joseph Carne	M	-	University of Massachusetts	5 years
David Laird Smith	M	-	University of Massachusetts	4 years
Rudolph F. Crew	M	73	University of Massachusetts	3 years
Jerrold L. Sklar	M	-	University of Massachusetts	4 years
Charles H. Steedman	M	-	University of Massachusetts	4 years
Karen Bailey	F	-	University of Massachusetts	4 years
Lewis Evangelidis	M	-	University of Massachusetts	4 years
Steve Chipman	M	-	University of Massachusetts	4 years
Mary Thistle	F	64	University of Massachusetts	4 years

Statistics

Country	Connections	% of total
United States	89	89.00%
Ireland	10	10.00%
Canada	1	1.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections